ExtraLife
The Hair Cell Shield
Humanin S14G (HNG) — Mitochondrial-Derived Peptide
Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP) originally discovered in 2001 as a neuroprotective factor. The synthetic analog HNG (Humanin S14G) has 1,000x greater potency. Recent breakthrough research has demonstrated direct protective effects on cochlear hair cells exposed to ototoxic damage, making it a compelling candidate for hearing preservation and tinnitus research.
Humanin activates the AKT survival pathway in cochlear cells, promoting cell survival and preventing apoptosis (programmed cell death) in hair cells exposed to ototoxic stress.
Activates the PI3K/AKT survival signaling pathway, the primary anti-apoptotic mechanism in cochlear hair cells.
Directly protects cochlear hair cells from aminoglycoside-induced and cisplatin-induced ototoxicity.
Functions as a retrograde signal from mitochondria, representing a newly understood class of endogenous protective peptides.
The S14G substitution (HNG) confers approximately 1,000x greater biological potency compared to wild-type Humanin.
Published research demonstrates direct protective effects on cochlear hair cells exposed to ototoxic damage, with significant hair cell survival improvement.
Originally discovered as a neuroprotective factor, Humanin protects against neuronal cell death in multiple contexts including Alzheimer's-related toxicity.
Activates survival pathways that prevent programmed cell death in vulnerable sensory cells, with particular relevance to the irreversible nature of hair cell loss.
HNG demonstrated direct protective effects on cochlear hair cells exposed to ototoxic damage, with significant improvement in hair cell survival rates via AKT pathway activation.
Mitochondrial-derived peptides including Humanin showed protective effects on cochlear hair cells, establishing MDPs as a new class of otoprotective compounds.
Humanin is a naturally occurring mitochondrial-derived peptide. The synthetic analog HNG has been studied primarily in preclinical models. Human safety data is limited but the endogenous nature of the peptide suggests a favorable safety profile.
Research Status
Humanin otoprotection research was published in Nature Cell Death Discovery (2024) and BBRC (2023). This represents breakthrough preclinical evidence for a new class of hearing-protective compounds. Human clinical trials have not yet begun for this indication.
Regulatory Note
Humanin (HNG) is not FDA-approved and is classified as a research compound. It is under investigation for hearing protection and neurodegenerative conditions.